Enliven Therapeutics
ELVN
ELVN
134 hedge funds and large institutions have $1.22B invested in Enliven Therapeutics in 2025 Q3 according to their latest regulatory filings, with 20 funds opening new positions, 59 increasing their positions, 32 reducing their positions, and 10 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding
Funds holding: →
more capital invested
Capital invested by funds: $ → $
14% less funds holding in top 10
Funds holding in top 10: 7 → 6 (-1)
20.85% less ownership
Funds ownership: 121.12% → 100.28% (-21%)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $1.4M
Holders
134
Holding in Top 10
6
Calls
–
Puts
$1.4M
Top Buyers
| 1 | +$18.6M | |
| 2 | +$11.3M | |
| 3 | +$9.92M | |
| 4 |
Pictet Asset Management
Carouge,
Switzerland
|
+$8.81M |
| 5 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
+$7M |
Top Sellers
| 1 | -$17M | |
| 2 | -$16.4M | |
| 3 | -$16.4M | |
| 4 |
TCM
TCG Crossover Management
Palo Alto,
California
|
-$9.99M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$8.82M |
